HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Go back to HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 109.86 +2.92 (2.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $106.94 | 52 Week High | $18.39 | |||
| Open | $106.96 | 52 Week Low | $6.96 | |||
| Day High | $109.99 | P/E | N/A | |||
| Day Low | $106.65 | EPS | $-0.58 | |||
| Volume | 2,614,340 | |||||
